BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 24745672)

  • 21. Mastocytosis: advances in diagnosis and treatment.
    Hungness SI; Akin C
    Curr Allergy Asthma Rep; 2007 Jul; 7(4):248-54. PubMed ID: 17547845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnosis and management of mastocytosis: an emerging challenge in applied hematology.
    Valent P
    Hematology Am Soc Hematol Educ Program; 2015; 2015():98-105. PubMed ID: 26637707
    [TBL] [Abstract][Full Text] [Related]  

  • 23. KIT and mastocytosis.
    Lim KH; Pardanani A; Tefferi A
    Acta Haematol; 2008; 119(4):194-8. PubMed ID: 18566536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mastocytosis: from a Molecular Point of View.
    Komi DEA; Rambasek T; Wöhrl S
    Clin Rev Allergy Immunol; 2018 Jun; 54(3):397-411. PubMed ID: 28725969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors.
    Shomali W; Gotlib J
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804174
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis.
    Wilson TM; Maric I; Simakova O; Bai Y; Chan EC; Olivares N; Carter M; Maric D; Robyn J; Metcalfe DD
    Haematologica; 2011 Mar; 96(3):459-63. PubMed ID: 21134978
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of oncostatin M as a STAT5-dependent mediator of bone marrow remodeling in KIT D816V-positive systemic mastocytosis.
    Hoermann G; Cerny-Reiterer S; Perné A; Klauser M; Hoetzenecker K; Klein K; Müllauer L; Gröger M; Nijman SM; Klepetko W; Valent P; Mayerhofer M
    Am J Pathol; 2011 May; 178(5):2344-56. PubMed ID: 21457934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. KIT GNNK splice variants: expression in systemic mastocytosis and influence on the activating potential of the D816V mutation in mast cells.
    Chan EC; Bai Y; Bandara G; Simakova O; Brittain E; Scott L; Dyer KD; Klion AD; Maric I; Gilfillan AM; Metcalfe DD; Wilson TM
    Exp Hematol; 2013 Oct; 41(10):870-881.e2. PubMed ID: 23743299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells.
    Soucie E; Hanssens K; Mercher T; Georgin-Lavialle S; Damaj G; Livideanu C; Chandesris MO; Acin Y; Létard S; de Sepulveda P; Hermine O; Bernard OA; Dubreuil P
    Blood; 2012 Dec; 120(24):4846-9. PubMed ID: 23074272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease.
    Hoermann G; Gleixner KV; Dinu GE; Kundi M; Greiner G; Wimazal F; Hadzijusufovic E; Mitterbauer G; Mannhalter C; Valent P; Sperr WR
    Allergy; 2014 Jun; 69(6):810-3. PubMed ID: 24750133
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives.
    Arock M; Valent P
    Expert Rev Hematol; 2010 Aug; 3(4):497-516. PubMed ID: 21083038
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CCL2 is a KIT D816V-dependent modulator of the bone marrow microenvironment in systemic mastocytosis.
    Greiner G; Witzeneder N; Berger A; Schmetterer K; Eisenwort G; Schiefer AI; Roos S; Popow-Kraupp T; Müllauer L; Zuber J; Sexl V; Kenner L; Sperr WR; Valent P; Mayerhofer M; Hoermann G
    Blood; 2017 Jan; 129(3):371-382. PubMed ID: 27856463
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis.
    Gotlib J; Schwaab J; Shomali W; George TI; Radia DH; Castells M; Carter MC; Hartmann K; Álvarez-Twose I; Brockow K; Bonadonna P; Hermine O; Niedoszytko M; Hoermann G; Sperr WR; Elberink HO; Siebenhaar F; Butterfield JH; Ustun C; Zanotti R; Triggiani M; Schwartz LB; Lyons JJ; Orfao A; Sotlar K; Horny HP; Arock M; Metcalfe DD; Akin C; Lübke J; Valent P; Reiter A
    J Allergy Clin Immunol Pract; 2022 Aug; 10(8):2025-2038.e1. PubMed ID: 35724948
    [TBL] [Abstract][Full Text] [Related]  

  • 34. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients.
    Garcia-Montero AC; Jara-Acevedo M; Teodosio C; Sanchez ML; Nunez R; Prados A; Aldanondo I; Sanchez L; Dominguez M; Botana LM; Sanchez-Jimenez F; Sotlar K; Almeida J; Escribano L; Orfao A
    Blood; 2006 Oct; 108(7):2366-72. PubMed ID: 16741248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD).
    Sotlar K; Colak S; Bache A; Berezowska S; Krokowski M; Bültmann B; Valent P; Horny HP
    J Pathol; 2010 Apr; 220(5):586-95. PubMed ID: 20112369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts.
    Valent P; Akin C; Arock M; Gleixner KV; Greinix H; Hermine O; Horny HP; Ivanov D; Orfao A; Rabitsch W; Reiter A; Schulenburg A; Sotlar K; Sperr WR; Ustun C
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of mi transcription factor (MITF) mRNA in a case of myelodysplastic syndrome and bone marrow mastocytosis.
    Wimazal F; Walchshofer S; Baghestanian M; Chott A; Sperr WR; Kopp C; Sillaber C; Semper H; Horny HP; Tröndle U; Födinger M; Schwarzinger I; Lechner K; Valent P
    Wien Klin Wochenschr; 1998 Feb; 110(3):79-88. PubMed ID: 9553202
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New Insights into the Pathogenesis of Mastocytosis: Emerging Concepts in Diagnosis and Therapy.
    Valent P; Akin C; Sperr WR; Horny HP; Arock M; Metcalfe DD; Galli SJ
    Annu Rev Pathol; 2023 Jan; 18():361-386. PubMed ID: 36270293
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mastocytosis.
    Metcalfe DD
    Novartis Found Symp; 2005; 271():232-42; discussion 242-9. PubMed ID: 16605139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnosis, progression patterns and prognostication in mastocytosis.
    Sperr WR; Valent P
    Expert Rev Hematol; 2012 Jun; 5(3):261-74. PubMed ID: 22780207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.